CDW Forensic analysis

HOLDConviction: 6/10Price: $104.3510-Q
Loading technical data…

Price Targets (12m)

Bull Case
$145.00
+39.0% from current
Base Case
$125.00
+19.8% from current
Bear Case
$90.00
-13.8% from current

Detailed research

PART 1: TRADING EXECUTION

Trading Setup & Entry Strategy

CDW is currently in a significant technical downdraft, trading roughly 26% off its recent highs. While the fundamental thesis remains solid, the technicals are flashing a bearish trend breakdown. We are looking for a structural floor before deploying capital.

  • >Entry Zone: $98.00 - $101.00. We want to see a stabilization near the psychological $100 support level before entering the first 30% tranche.
  • >Stop Loss: $92.00 (Hard Stop). This sits just above the lower Bollinger Band ($87.26) and provides room for volatility while cutting exposure if the support fails.
  • >Scaling Strategy: Enter 30% at $100.50. Add 40% only on a successful re-test of the 10-day SMA ($103.89) to confirm trend reversal. Final 30% on a breakout above the 50-day SMA ($122.18).
  • >Risk/Reward: Target $125 (Resistance) from a $100 average entry = ~1:1 R/R on short term, 1:2.5 on base case recovery.
  • >Max Hold: 4 weeks, with a review at the next quarterly update.

PART 2: DETAILED RESEARCH

Executive Summary

CDW is a high-quality IT solutions provider currently suffering from a valuation compression and negative sentiment divergence. Despite a 9.2% revenue increase YOY, the stock has been punished due to macro-uncertainty and margin compression. Conviction Score: 6/10 (Waiting for technical pivot).

Recent Material Events & News

  • >Buyback Expansion: On May 13, 2026, CDW authorized an additional $1.00B share buyback, signaling management’s belief that the current $104.35 price is an undervaluation.
  • >Earnings Pulse: Q1 2026 earnings were a beat, but the market focused on the 60bps margin compression (21.0% vs 21.6%) and caution regarding IT spending cycles.
  • >Analyst Sentiment: UBS recently cut PT to $147 from $162, signaling a lowered near-term growth expectation despite maintaining a 'Buy' rating.

Forensic Accounting & Financial Health

  • >Revenue Quality: Strong. Revenue growth of 9.2% is healthy, but the cash conversion cycle increased to 16 days from 15, reflecting higher inventory positions.
  • >Debt Profile: Stable. Total debt is $5.60B, with sufficient liquidity ($1.90B available on the Revolving Credit Facility).
  • [WARN]Profitability: Net income grew 4.7% YOY. However, selling and administrative expenses grew 7.0%, outpacing net income, which is a **minor red flag **.

Technical Analysis & Trade Timing

  • >Momentum: The stock is currently in a BEARISH_DOWNTREND with a 20-day return of -26.21%. The RSI of 32.10 is approaching OVERSOLD territory but has not yet triggered a bounce.
  • >Reconciliation: While the $1B buyback is fundamentally bullish (value signal), the chart is in a 'death spiral' relative to moving averages (Price 25.75% below 200-day SMA). We must respect the technicals and wait for a reversal confirmation rather than front-running the bounce.

Short-Term Trading Strategy (2-5 Days)

  • >Timeframe: Swing Trade (2–5 Days) (Wait for base formation).
  • >Risk-Reward: Aiming for 1:2.3.
  • >Catalyst: Monitoring for a 'bullish engulfing' daily candle to signal the end of the 20-day liquidation.

One-Liner Thesis: CDW is a 'value play' in a broken trend; the $1B buyback provides a firm floor, but wait for the RSI to bounce off the 30-level before committing to the long side.